GSK’s Benlysta Approved to Treat Active Lupus Nephritis

By Sam | December 17, 2020

GlaxoSmithKline has received FDA approval for Benlysta (belimumab) to treat active lupus nephritis, a serious inflammation of the kidneys that appears in about four in 10 patients with the most common form of lupus. The inflammation can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.
Source: Drug Industry Daily

Posted in Drug Industry Daily